SCHEMBL30173290

SCHEMBL30173290

Clc1c(-c2ccc3ccccc3c2)cnc2[nH]ccc12

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 2/20 0.51
AXL P30530 2/20 0.48
NUDT1 P36639 2/20 0.45
DHFR P00374 1/20 0.44
CLK1 P49759 1/20 0.44
MAP3K11 Q16584 2/20 0.43
CDK8 P49336 2/20 0.43
CCNK O75909 1/20 0.43
CDK12 Q9NYV4 1/20 0.43
ADORA2A P29274 1/20 0.42
ADORA1 P30542 1/20 0.42
SGK1 O00141 3/20 0.41
PIK3CD O00329 1/20 0.41
PIK3CB P42338 1/20 0.41
PIK3CG P48736 1/20 0.41
KDM4E B2RXH2 1/20 0.40
JAK2 O60674 2/20 0.40
IKBKB O14920 1/20 0.40
CHUK O15111 1/20 0.40
DAPK3 O43293 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28603791 1.00 PRKCI (0.51) PRKCIAXLNUDT1DHFRCLK1
SCHEMBL28602138 0.83 CCNK (0.49) PRKCIAXLNUDT1MAP3K11CCNK
SCHEMBL30173270 0.83 CCNK (0.49) PRKCIAXLNUDT1MAP3K11CCNK
SCHEMBL30173305 0.82 JAK2 (0.58) PRKCIAXLNUDT1CDK8CCNK
SCHEMBL3725709 0.82 JAK2 (0.58) PRKCIAXLNUDT1CDK8CCNK
SCHEMBL28596878 0.82 NUDT1 (0.51) PRKCIAXLNUDT1MAP3K11CDK8
SCHEMBL28606321 0.80 NUDT1 (0.68) PRKCIAXLNUDT1DHFRCDK8
SCHEMBL30173337 0.80 NUDT1 (0.68) PRKCIAXLNUDT1DHFRCDK8
SCHEMBL30173298 0.79 RPS6KA3 (0.49) PRKCIAXLNUDT1CDK8CCNK
SCHEMBL28596894 0.79 RPS6KA3 (0.49) PRKCIAXLNUDT1CDK8CCNK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113200983-B Compound with pyrrolopyridine structure, preparation method and medical application 中国药科大学 2023-01-03 CN disclosed